Bailard’s CVS Health CVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.19M | Hold |
11,520
| – | – | 0.02% | 323 |
|
|
2026
Q1 | $827K | Hold |
11,520
| – | – | 0.02% | 365 |
|
|
2025
Q4 | $914K | Sell |
11,520
-4,983
| -30% | -$393K | 0.02% | 332 |
|
|
2025
Q3 | $1.24M | Buy |
16,503
+29
| +0.2% | +$1.99K | 0.03% | 304 |
|
|
2025
Q2 | $1.14M | Sell |
16,474
-200
| -1% | -$13.1K | 0.03% | 306 |
|
|
2025
Q1 | $1.13M | Buy |
16,674
+2,875
| +21% | +$172K | 0.03% | 289 |
|
|
2024
Q4 | $619K | Sell |
13,799
-302
| -2% | -$16.9K | 0.02% | 421 |
|
|
2024
Q3 | $887K | Sell |
14,101
-866
| -6% | -$50.5K | 0.02% | 328 |
|
|
2024
Q2 | $884K | Sell |
14,967
-10,662
| -42% | -$667K | 0.02% | 314 |
|
|
2024
Q1 | $2.04M | Sell |
25,629
-92,414
| -78% | -$7.06M | 0.06% | 225 |
|
|
2023
Q4 | $9.32M | Buy |
118,043
+6
| +0% | +$427 | 0.28% | 82 |
|
|
2023
Q3 | $8.24M | Buy |
118,037
+16,117
| +16% | +$1.14M | 0.27% | 82 |
|
|
2023
Q2 | $7.05M | Sell |
101,920
-4,835
| -5% | -$344K | 0.25% | 89 |
|
|
2023
Q1 | $7.93M | Buy |
106,755
+755
| +0.7% | +$63.3K | 0.28% | 82 |
|
|
2022
Q4 | $9.88M | Buy |
106,000
+14,822
| +16% | +$1.43M | 0.38% | 61 |
|
|
2022
Q3 | $8.7M | Buy |
91,178
+4,539
| +5% | +$449K | 0.36% | 63 |
|
|
2022
Q2 | $8.03M | Buy |
86,639
+2,293
| +3% | +$224K | 0.32% | 71 |
|
|
2022
Q1 | $8.54M | Buy |
84,346
+2,514
| +3% | +$264K | 0.29% | 83 |
|
|
2021
Q4 | $8.44M | Buy |
81,832
+787
| +1% | +$72.7K | 0.27% | 87 |
|
|
2021
Q3 | $6.88M | Buy |
81,045
+2,340
| +3% | +$196K | 0.24% | 99 |
|
|
2021
Q2 | $6.57M | Buy |
78,705
+2,349
| +3% | +$192K | 0.23% | 101 |
|
|
2021
Q1 | $5.74M | Buy |
76,356
+2,303
| +3% | +$168K | 0.21% | 103 |
|
|
2020
Q4 | $5.06M | Sell |
74,053
-149
| -0.2% | -$9.69K | 0.23% | 91 |
|
|
2020
Q3 | $4.33M | Buy |
74,202
+305
| +0.4% | +$19K | 0.22% | 88 |
|
|
2020
Q2 | $4.8M | Buy |
73,897
+6,457
| +10% | +$407K | 0.27% | 79 |
|
|
2020
Q1 | $4M | Buy |
67,440
+8,501
| +14% | +$567K | 0.28% | 81 |
|
|
2019
Q4 | $4.38M | Buy |
58,939
+16,138
| +38% | +$1.13M | 0.25% | 91 |
|
|
2019
Q3 | $2.7M | Buy |
42,801
+88
| +0.2% | +$5.21K | 0.16% | 129 |
|
|
2019
Q2 | $2.33M | Buy |
42,713
+898
| +2% | +$48.4K | 0.14% | 142 |
|
|
2019
Q1 | $2.25M | Buy |
41,815
+3,227
| +8% | +$199K | 0.14% | 150 |
|
|
2018
Q4 | $2.53M | Sell |
38,588
-12,163
| -24% | -$908K | 0.17% | 122 |
|
|
2018
Q3 | $4M | Sell |
50,751
-2,420
| -5% | -$173K | 0.23% | 96 |
|
|
2018
Q2 | $3.42M | Sell |
53,171
-3,167
| -6% | -$209K | 0.2% | 109 |
|
|
2018
Q1 | $3.5M | Buy |
56,338
+4,121
| +8% | +$296K | 0.22% | 108 |
|
|
2017
Q4 | $3.79M | Sell |
52,217
-8,316
| -14% | -$605K | 0.24% | 101 |
|
|
2017
Q3 | $4.92M | Buy |
60,533
+2,109
| +4% | +$167K | 0.38% | 66 |
|
|
2017
Q2 | $4.7M | Buy |
58,424
+3,985
| +7% | +$315K | 0.38% | 66 |
|
|
2017
Q1 | $4.27M | Buy |
54,439
+606
| +1% | +$48.4K | 0.35% | 73 |
|
|
2016
Q4 | $4.25M | Buy |
53,833
+3,907
| +8% | +$316K | 0.39% | 65 |
|
|
2016
Q3 | $4.44M | Buy |
49,926
+24,695
| +98% | +$2.33M | 0.41% | 64 |
|
|
2016
Q2 | $2.42M | Buy |
+25,231
| New | +$2.51M | 0.29% | 80 |
|
Other funds holding CVS
Bailard's CVS Position: Q2 2026 in Review
Bailard held its CVS Health (CVS) position steady in Q2 2026 at 11,520 shares worth $1.19M. The position accounts for 0.02% of the portfolio, ranked #323.
Bailard first reported a position in CVS in Q2 2016 and has held it in 41 quarters since. The position peaked at $9.88M in Q4 2022. 2,061 funds tracked by Wall St. Rank hold CVS as of Q2 2026.
- Bailard held 11,520 shares of CVS Health worth $1.19M as of Q2 2026.
- Bailard left its CVS Health share count unchanged in Q2 2026.
- CVS Health made up 0.02% of Bailard's portfolio in Q2 2026, its #323 holding.
- Bailard first reported a position in CVS Health in Q2 2016 and has held it in 41 quarters since.
- Bailard's CVS Health position peaked at $9.88M in Q4 2022.
- 2,061 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.
Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.